Drug class
COVID-19 (SARS-CoV-2) Vaccines
COVID-19 (SARS-CoV-2) vaccines constitute a biological class of active immunizing agents designed to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2. Read more about COVID-19 (SARS-CoV-2) Vaccines
8 drugs in this class 3 manufacturers
Drugs in COVID-19 (SARS-CoV-2) Vaccines
COMIRNATY 2025-2026(5-11Y) (COVID vacc 2025-2026 (5-11 years) (Pfizer)/PF)
MNEXSPIKE 2026-2027 (12Y UP) (COVID vaccine 2026-2027 (12 years up) (Moderna)/PF)
SPIKEVAX 2026-2027 (12Y UP) (COVID vaccine 2026-2027 (12 years up) (Moderna)/PF)
SPIKEVAX 2026-2027 (6M-11Y) (COVID vaccine 2026-2027 (6 months-11 years)(Moderna)/PF)
COMIRNATY 2026-2027 (12Y UP) (COVID vaccine 2026-2027 (12 yrs up) (Pfizer)/PF)
COMIRNATY 2026-2027(5-11Y) (COVID vacc 2026-2027 (5-11 years) (Pfizer)/PF)
NUVAXOVID 2026-2027 (COVID vaccine 2026-2027 (12 yrs up)/adjuvant-Matrix/PF)
COVID-19 (SARS-CoV-2) vaccines constitute a biological class of active immunizing agents designed to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2.
Utilizing platforms such as messenger RNA, recombinant protein subunits, or viral vectors, these vaccines introduce or instruct host cells to transiently express antigenic targets—primarily the viral spike glycoprotein—stimulating robust humoral neutralizing antibody and cell-mediated immune responses.
Their principal therapeutic role is the pre-exposure prophylaxis of SARS-CoV-2 infection, substantially reducing the risks of symptomatic infection, severe lower respiratory disease, hospitalization, and mortality.
-
tdl.org
COVID-19 (SARS-CoV-2) vaccines constitute a biological class of active immunizing agents designed to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2
-
nih.gov
COVID-19 (SARS-CoV-2) vaccines constitute a biological class of active immunizing agents designed to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2
-
nih.gov
Utilizing platforms such as messenger RNA, recombinant protein subunits, or viral vectors, these vaccines introduce or instruct host cells to transiently express antigenic targets—primarily the viral spike glycoprotein—stimulating robust humoral neutralizing antibody and cell-mediated immune responses
-
mdpi.com
Utilizing platforms such as messenger RNA, recombinant protein subunits, or viral vectors, these vaccines introduce or instruct host cells to transiently express antigenic targets—primarily the viral spike glycoprotein—stimulating robust humoral neutralizing antibody and cell-mediated immune responses
-
nih.gov
Utilizing platforms such as messenger RNA, recombinant protein subunits, or viral vectors, these vaccines introduce or instruct host cells to transiently express antigenic targets—primarily the viral spike glycoprotein—stimulating robust humoral neutralizing antibody and cell-mediated immune responses Their principal therapeutic role is the pre-exposure prophylaxis of SARS-CoV-2 infection, substantially reducing the risks of symptomatic infection, severe lower respiratory disease, hospitalizatio...
-
mayoclinic.org
Utilizing platforms such as messenger RNA, recombinant protein subunits, or viral vectors, these vaccines introduce or instruct host cells to transiently express antigenic targets—primarily the viral spike glycoprotein—stimulating robust humoral neutralizing antibody and cell-mediated immune responses
-
nih.gov
Their principal therapeutic role is the pre-exposure prophylaxis of SARS-CoV-2 infection, substantially reducing the risks of symptomatic infection, severe lower respiratory disease, hospitalization, and mortality
-
medlineplus.gov
Their principal therapeutic role is the pre-exposure prophylaxis of SARS-CoV-2 infection, substantially reducing the risks of symptomatic infection, severe lower respiratory disease, hospitalization, and mortality
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.